Patents Assigned to Celgene Avilomics Research, Inc.
  • ERK inhibitors and uses thereof
    Patent number: 9561228
    Abstract: Compounds, compositions thereof, and methods for inhibiting one or both ERK1 and ERK2 kinases are provided.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: February 7, 2017
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • Protein kinase conjugates and inhibitors
    Patent number: 9556426
    Abstract: The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: January 31, 2017
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu
  • Heteroaryl compounds and uses thereof
    Patent number: 9549927
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: January 24, 2017
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Richland Tester, Prasoon Chaturvedi, Zhendong Zhu, Sekhar S. Surapaneni, Lisa Beebe
  • Salts of an epidermal growth factor receptor kinase inhibitor
    Patent number: 9540335
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: January 10, 2017
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • Solid forms of an epidermal growth factor receptor kinase inhibitor
    Patent number: 9539255
    Abstract: The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: January 10, 2017
    Assignee: CELGENE AVILOMICS RESEARCH, INC.
    Inventor: Mei Lai
  • ERK inhibitors and uses thereof
    Patent number: 9504686
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: November 29, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
    Patent number: 9492471
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: November 15, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Tom Daniel, Kenichi Takeshita, Kenneth Foon, Jay Mei
  • MK2 inhibitors and uses thereof
    Patent number: 9458175
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 4, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Matthew David Alexander, Claudio Chuaqui, John Malona, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Juswinder Singh, Chittari Pabba
  • HCV protease inhibitors and uses thereof
    Patent number: 9422333
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: August 23, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh
  • Heteroaryl compounds and uses thereof
    Patent number: 9415049
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: August 16, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Richland Tester, Prasoon Chaturvedi, Zhendong Zhu, Sekhar S. Surapaneni, Lisa Beebe
  • Mutant-selective EGFR inhibitors and uses thereof
    Patent number: 9409887
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: August 9, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Kwangho Lee, Deqiang Niu, Matthew F. Baevsky
  • 2,4-disubstituted pyrimidines as kinase inhibitors
    Patent number: 9409921
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: August 9, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • 4,6-disubstituted pyrimidines as kinase inhibitors
    Patent number: 9393246
    Abstract: The present invention provides 4,6-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: July 19, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur Kluge, Russell C. Petter, Richland W. Tester
  • 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors
    Patent number: 9375431
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: June 28, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Kwangho Lee, Deqiang Niu, Russell C. Petter, Matthew F. Baevsky, Juswinder Singh
  • Methods of treating a Bruton's Tyrosine Kinase disease or disorder
    Patent number: 9364476
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: June 14, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Steven Richard Witowski, William Frederick Westlin, III, Heather Lounsbury, Kathryn Stiede, Bruce A. Silver, Jay M. Mei
  • Heteroaryl compounds and uses thereof
    Patent number: 9321786
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 26, 2016
    Assignees: Celgene Avilomics Research, Inc., Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • Substituted pyrimidines as protein kinase inhibitors
    Patent number: 9296704
    Abstract: The present invention provides 4,6-diaminopyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: March 29, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur F. Kluge, Russell C. Petter, Richland W. Tester
  • Substituted 2,4-diaminopyrimidines as kinase inhibitors
    Patent number: 9296737
    Abstract: The present invention provides 2,4-diaminopyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: March 29, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Heteroaryl compounds and uses thereof
    Patent number: 9238629
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: January 19, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Kwangho Lee, Deqiang Niu, Russell C. Petter, Juswinder Singh
  • ERK INHIBITORS AND USES THEREOF
    Publication number: 20160002176
    Abstract: Compounds, compositions thereof, and methods for inhibiting one or both ERK1 and ERK2 kinases are provided.
    Type: Application
    Filed: February 7, 2014
    Publication date: January 7, 2016
    Applicant: Celgene Avilomics Research, Inc.
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu